OSE IMMUNOTHERAPEUTICS (OSE.PA)
OSE IMMUNOTHERAPEUTICS reported revenue of 2.6M EUR for the year ending 31 December 2025, down 96.3% from 69.9M a year earlier.
Every figure below is the company's own, as filed. Nothing is estimated and
nothing is smoothed — a period the filing does not support is left blank rather than
filled in.
Quarters are the company's own, counted from its financial
year ending 12-31.
Amounts in EUR.
The same series drawn ›
As last reported
The newest period the filing supports for each figure, in EUR.
| Figure | Period | Amount | Year on year |
|---|
| Revenue |
2025 · ending 31 December 2025 |
2.6M |
-96.3% |
| Operating Income |
2025 · ending 31 December 2025 |
-37.5M |
-185.7% |
| Net Income |
2025 · ending 31 December 2025 |
-37.7M |
-200.7% |
| Operating Cash Flow |
2025 · ending 31 December 2025 |
-34M |
-170.3% |
Revenue and profit by financial year
As filed, in EUR. A year the filing does not support is not listed.
| Year | Ending |
Revenue | Operating Income | Net Income | Free Cash Flow |
|---|
| 2025 | 2025-12-31 |
2.6M | -37.5M | -37.7M | — |
|---|
| 2024 | 2024-12-31 |
69.9M | 43.7M | 37.4M | — |
|---|
| 2023 | 2023-12-31 |
2.2M | -23M | -23M | — |
|---|
| 2021 | 2021-12-31 |
26.3M | -16.6M | -16.9M | — |
|---|
| 2020 | 2020-12-31 |
10.4M | -19M | -16.6M | — |
|---|
Every period
Revenue Annual
| Period | Ending | Revenue |
|---|
| FY25 | 2025-12-31 | 2.6M |
|---|
| FY24 | 2024-12-31 | 69.9M |
|---|
| FY23 | 2023-12-31 | 2.2M |
|---|
| FY21 | 2021-12-31 | 26.3M |
|---|
| FY20 | 2020-12-31 | 10.4M |
|---|
Operating Income Annual
| Period | Ending | Operating Income |
|---|
| FY25 | 2025-12-31 | -37.5M |
|---|
| FY24 | 2024-12-31 | 43.7M |
|---|
| FY23 | 2023-12-31 | -23M |
|---|
| FY21 | 2021-12-31 | -16.6M |
|---|
| FY20 | 2020-12-31 | -19M |
|---|
Net Income Annual
| Period | Ending | Net Income |
|---|
| FY25 | 2025-12-31 | -37.7M |
|---|
| FY24 | 2024-12-31 | 37.4M |
|---|
| FY23 | 2023-12-31 | -23M |
|---|
| FY21 | 2021-12-31 | -16.9M |
|---|
| FY20 | 2020-12-31 | -16.6M |
|---|
Operating Cash Flow Annual
| Period | Ending | Operating Cash Flow |
|---|
| FY25 | 2025-12-31 | -34M |
|---|
| FY24 | 2024-12-31 | 48.4M |
|---|
| FY23 | 2023-12-31 | -19.8M |
|---|
| FY21 | 2021-12-31 | -9.9M |
|---|
| FY20 | 2020-12-31 | -19.6M |
|---|